Decision Resources, one of the world's leading research and advisory
firms for pharmaceutical and healthcare issues, finds that, through 2017,
robust 3.6 percent annual growth in the non-Hodgkin's lymphoma drug market
will be driven by increasing market penetration of Biogen
Idec/Genentech/Chugai/Zenyaku Kogyo's Rituxan/Roche's MabThera, particularly
in the chronic lymphocytic leukemia market.
The new Pharmacor report entitled Non-Hodgkin's Lymphoma finds that the
development of therapies for the treatment of non-Hodgkin's lymphoma remains
highly challenging because of the dominance Rituxan/MabThera holds across the
subpopulations of the disease in the United States, France, Germany, Italy,
Spain, the United Kingdom and Japan. The report finds that Rituxan/MabThera
will continue to dominate the non-Hodgkin's lymphoma market as interviewed
thought leaders say they are satisfied with the drug's safety and efficacy
and they do not expect to significantly utilize any late-stage emerging
agents over the next decade.
Although sales of GlaxoSmithKline/Genmab's ofatumumab will grow at an
impressive annual rate of 8.4 percent from 2012 to 2017 following its
expected launch in 2009, it will not take significant patient share away from
Rituxan/MabThera.
"Rituxan/MabThera will continue to dominate the non-Hodgkin's lymphoma
market over the next decade, owing to its widespread use in combination
chemotherapy regimens in all non-Hodgkin's lymphoma patient segments, and it
will retain its dominance despite the expected market entry of biosimilars,"
said Andrew Merron, Ph.D., analyst at Decision Resources.
About Decision Resources
Decision Resources is a world leader
in market research publications, advisory services and consulting designed to
help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of
the healthcare industry. Clients rely on this analysis and data to make
informed decisions.
Decision Resources, Inc.